Sun Pharma Signed an MFN Drug Deal With the US — Here's Who Else Gets Hit, and Who Quietly Wins

Sun Pharma Signed an MFN Drug Deal With the US — Here's Who Else Gets Hit, and Who Quietly Wins

Sun Pharmaceutical Industries, India's largest pharma company, has agreed to offer "Most Favoured Nation" pricing on its drugs in the United States — essentially capping what it can charge American buyers at the lowest price it offers anywhere in the world. The deal delays threatened tariffs on innovative medicines, but it marks a fundamental shift in how Indian pharma companies will need to price their products in the world's largest drug market.

Everyone's focused on Sun Pharma. But the real story is what this means for the rest of Indian pharma — and who comes out ahead.

The MFN Framework: What's Actually Happening

Per Sun Pharma Advanced Research Company's FY26 annual report, the MFN pharmaceutical pricing policy has evolved into a comprehensive framework combining voluntary manufacturer agreements with three regulatory models: GENEROUS for Medicaid, GLOBE for Medicare Part B, and GUARD for Medicare Part D. The goal is to benchmark US drug prices against those paid in other developed nations.

Crucially, participating companies have collectively committed to invest at least US$150 billion in US-based manufacturing in the near term. This isn't just about pricing — it's about onshoring production.

The Exposed: Indian Generics Giants With Heavy US Revenue

Sun Pharma (SUNPHARMA) itself has the most at stake. Per its Q4 FY25 board outcome, US formulation sales for FY25 were US$1,921 million — roughly 31% of consolidated revenue. Its innovative medicines portfolio crossed US$1 billion in the US for the first time in FY26, per its Q4 FY26 earnings call transcript. That innovative portfolio is precisely what MFN pricing targets hardest. Cipla (CIPLA) hit an all-time high of US$934 million in North America revenue for FY25, per its Q4 FY25 earnings call transcript, driven by strong traction in its differentiated portfolio including albuterol. With the US now a major growth engine, MFN pricing on its specialty products could compress margins on exactly the products driving Cipla's premium valuation. Lupin (LUPIN) has been on a tear in the US — North America revenue grew 16% year-on-year in FY25 to ₹83,950 million, per its FY25 investor presentation. The company noted US revenue per se grew 17%. But Lupin's strength in generics may actually provide a partial buffer: MFN pricing primarily targets innovative and specialty drugs, while generic pricing is already competitive. Dr. Reddy's (DRREDDY) faces a double bind. Per its FY26 annual report, North America generics contributed US$1.2 billion (34% of overall sales), but revenue already declined 22% year-on-year due to price erosion in key products. More critically, as its CEO noted in the Q4 FY25 earnings call, Dr. Reddy's has no manufacturing in the US — making it uniquely exposed to both tariff threats and the onshoring requirements embedded in MFN agreements.

The Quiet Winners: CDMOs With US Manufacturing

Here's the second-order effect nobody's talking about. The MFN framework doesn't just demand lower prices — it rewards companies that manufacture in the US. That creates a massive tailwind for Indian contract development and manufacturing organizations (CDMOs) that already have Western facilities.

Piramal Pharma (PPLPHARMA) is perhaps best positioned. Per its FY24 results presentation, 84% of CDMO revenue comes from regulated markets — 44% from the US alone, 35% from Europe. The company operates 15 manufacturing and development sites across the US, Europe, Canada, and India. Its differentiated offerings (antibody drug conjugates, high-potency APIs, sterile injectables) generated US$253 million in FY24, up from US$139 million in FY21. Per its Q1 FY26 press release, it's targeting US$2 billion in revenue by FY2030 with 25% EBITDA margins. Jubilant Pharmova (JUBLPHARMA) derives a staggering 80% of its revenue from the United States, per its FY26 annual report. But unlike formulators who face pricing pressure, Jubilant benefits as a contract manufacturer — it's a leading mid-sized CDMO in North America specializing in sterile fill-and-finish injectables, and the sole supplier of venom products in the US. Its CRDMO segment's EBITDA grew 32% to ₹2,238 million in FY25, per its FY25 annual report, even as revenue grew only 5% — a sign of improving pricing power.

What Retail Investors Should Do

Don't panic-sell your pharma holdings, but recalibrate your expectations. For companies like Sun Pharma, Cipla, and Dr. Reddy's, the US revenue contribution you've been cheering is now also a source of margin risk. Watch for management commentary on MFN compliance costs and pricing adjustments in upcoming quarterly results.

The contrarian play is in CDMOs. Piramal Pharma and Jubilant Pharmova have the US manufacturing footprint that the MFN framework rewards. If the onshoring trend accelerates — and US$150 billion in committed manufacturing investments suggests it will — these companies become the picks and shovels of the new US pharma order. Their order books in coming quarters will tell the story.

Data sourced from company filings on NSE via Xaro.